Free Trial

Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 7,942 Shares of Stock

Ultragenyx Pharmaceutical logo with Medical background

Key Points

  • Ultragenyx Pharmaceutical's CFO, Howard Horn, sold 7,942 shares of stock at an average price of $31.51, a move that decreased his holdings by 7.48%.
  • The company reported a negative EPS of ($1.17) for the last quarter, beating estimates, while revenue increased 13.2% year-over-year.
  • Analysts have mixed opinions on the stock, with an average target price of $81.50 and ratings ranging from Buy to Sell.
  • Five stocks we like better than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 7,942 shares of the company's stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the sale, the chief financial officer directly owned 98,227 shares in the company, valued at approximately $3,095,132.77. The trade was a 7.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Ultragenyx Pharmaceutical Stock Performance

RARE stock traded down $0.29 on Tuesday, reaching $31.74. The company had a trading volume of 487,578 shares, compared to its average volume of 1,348,129. Ultragenyx Pharmaceutical Inc. has a 1 year low of $25.81 and a 1 year high of $57.99. The company's fifty day moving average is $29.82 and its 200 day moving average is $32.94. The company has a market cap of $3.06 billion, a P/E ratio of -5.75 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. During the same quarter in the prior year, the company earned ($1.52) EPS. Ultragenyx Pharmaceutical's revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Institutional Trading of Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 323 shares during the last quarter. Xponance Inc. increased its holdings in Ultragenyx Pharmaceutical by 2.8% in the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock valued at $455,000 after purchasing an additional 347 shares in the last quarter. Oak Ridge Investments LLC increased its holdings in Ultragenyx Pharmaceutical by 2.3% in the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock valued at $643,000 after purchasing an additional 395 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in Ultragenyx Pharmaceutical by 1.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company's stock valued at $828,000 after purchasing an additional 404 shares in the last quarter. Finally, GF Fund Management CO. LTD. increased its holdings in Ultragenyx Pharmaceutical by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,364 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 425 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on RARE shares. Wedbush reduced their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research note on Monday, July 14th. Guggenheim reissued a "buy" rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Weiss Ratings reissued a "sell (e+)" rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Wells Fargo & Company reduced their price target on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday, July 10th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $105.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, September 5th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $81.50.

Read Our Latest Report on RARE

About Ultragenyx Pharmaceutical

(Get Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Further Reading

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ultragenyx Pharmaceutical Right Now?

Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.

While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.